[en] The chemical modification of clozapine (1) has permitted the finding of new analogues, e.g., olanzapine (2), quetiapine (3), 5-(4-methylpiperazin-1-yl)-8-chloropyrido[2,3-b][1,5]benzoxazepine fumarate (9), with a clinical or psychopharmacological profile similar to that of clozapine. However, when developing new derivatives, the designers are discouraged by the development of clozapine-induced agranulocytosis. Different researchers have raised the role played by the oxidizability of the molecule in such a deleterious effect. In the present paper, we examined the oxidation profile (direct scavenging abilities, efficacy in inhibiting lipid peroxidation, and electrooxidation potential) of newly developed methoxy and trifluoromethylsulfonyloxy analogues related to clozapine, some of them being described as putative antipsychotic. The oxazepine derivative 7, unlike the other diazepine derivatives (6, 10--12), was not readily oxidized. Using a statistical predictive model for hematotoxicity previously described, 7 was found in the cluster of potentially nontoxic compounds while diazepine derivatives 6 and 10-12 were classified as potentially toxic compounds. Among these original compounds, 7, which presents a preclinical clozapine-like profile and a low sensitivity to oxidation, could be a promising antipsychotic candidate with low side effects. Considering the tricyclic derivatives examined so far, some elements of structure-oxidation relationship (SOR) might be pointed out. Regarding the nature of the tricyclic ring substituent, from the most to the least sensitive to oxidation, the sequence was as follows: HO > Cl > CH(3)O > CF(3)SO(2)O. The nature of the tricyclic ring influenced also the sensitivity to oxidation; the diazepine moiety appeared to be the most reactive ring compared to oxa- and thiazepine congeners. These parameters could be advantageously integrated in the early design of new safer clozapine-like analogues.
Centre/Unité de recherche :
C.I.R.M.
Disciplines :
Pharmacie, pharmacologie & toxicologie
Auteur, co-auteur :
Mouithys-Mickalad, Ange ; Université de Liège - ULiège > Centre de l'oxygène : Recherche et développement (C.O.R.D.)
Kauffmann, J. M.
Petit, C.
Bruhwyler, J.
Liao, Y.
Wikstrom, H.
Damas, Jacques ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Delarge, J.
Deby-Dupont, G.
Geczy, J.
Liégeois, Jean-François ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Langue du document :
Anglais
Titre :
Electrooxidation Potential as a Tool in the Early Screening for New Safer Clozapine-Like Analogues
Date de publication/diffusion :
01 mars 2001
Titre du périodique :
Journal of Medicinal Chemistry
ISSN :
0022-2623
eISSN :
1520-4804
Maison d'édition :
American Chemical Society (ACS), Washington, Etats-Unis - District de Columbia
Volume/Tome :
44
Fascicule/Saison :
5
Pagination :
769-76
Peer reviewed :
Peer reviewed vérifié par ORBi
Organisme subsidiant :
F.R.S.-FNRS - Fonds de la Recherche Scientifique ULg FSR - Université de Liège. Fonds spéciaux pour la recherche
Kane J., Honigfeld G., Singer J., Meltzer H.Y. (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45:789-796.
Meltzer H.Y., Matsubara S., Lee J.-C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251:238-246.
Liégeois J.-F., Eyrolles L., Bruhwyler J., Delarge J. (1998) Dopamine D4 receptors: A new opportunity for research on schizophrenia. Curr. Med. Chem. 5:77-100.
Schauss J.M., Bymaster F.P. (1998) Dopaminergic approaches to antipsychotic agents., Annual Reports in Medicinal Chemistry; Bristol, J. A., Robertson, D. W., Eds.; Academic Press: San Diego, London; 33:1-10.
Bruhwyler J., Liégeois J.-F., Bergman J., Carey G., Goudie A., Taylor A., Meltzer H.Y., Delarge J., Géczy J. (1997) JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioural properties. Pharmacol. Res. 36:255-264.
Liégeois J.-F., Bruhwyler J., Damas J., Nguyen T.P., Chleide E., Mercier M., Rogister F., Delarge J. (1993) New pyridobenzodiazepine derivatives as potential antipsychotics: Synthesis and neurochemical study. J. Med. Chem. 36:2107-2114.
Liégeois J.-F., Rogister F., Bruhwyler J., Damas J., Nguyen T.P., Inarejos M.O., Chleide E., Mercier M., Delarge J. (1994) Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: Synthesis and neurochemical study. J. Med. Chem. 37:519-525.
Liao Y., DeBoer P., Meier E., Wikström H. (1997) Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine. Identification of a novel atypical neuroleptic. J. Med. Chem. 40:4146-4153.
Liao Y., Venhuis B.J., Rodenhuis N., Timmerman W., Wikström H., Meier E., Bartoszyk G.D., Böttcher H., Seyfried C.A., Sundell S. (1999) New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: Chemistry and pharmacological evaluation. J. Med. Chem. 42:2235-2244.
Guest J., Sokoluk B., MacCrimmon J., Uetrecht J. (1998) Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 131:53-65.
Pirmohamed M., Park K. (1997) Mechanism of clozapine-induced agranulocytosis. Current status of research and implications for drug development. CNS Drugs 7:139-158.
Laidlaw S.T., Snowden J.A., Brown M.J. (1993) Aplastic anaemia and remoxipride. Lancet 342:1245.
Uetrecht J. (1989) Idiosyncratic reactions drug reactions: Possible role of reactive metabolites generated by leukocytes. Pharm. Res. 6:265-273.
Van der Klauw M.M., Wilson J.H.P., Stricker B.H.Ch. (1998) Drug-associated agranulocytosis: 20 Years of reporting in the Netherlands (1974-1994). Am. J. Hematol. 57:206-211.
Fischer V., Haar J.A., Greiner L., Lloyd R.V., Mason R.P. (1991) Possible role of free radical formation in clozapine (Clozaril)-induced agranulocytosis. Mol. Pharmacol. 40:846-853.
Uetrecht J.P. (1996) Reactive metabolites and agranulocytosis. Eur. J. Haematol. 57:83-88.
Uetrecht J., Zahid N., Tehim A., Mimfu J., Rakhit S. (1997) Structural features associated with reactive metabolite formation in clozapine analogues. Chem. Biol. Interact. 104:117-129.
Liégeois J.-F., Rogister F., Delarge J., Pincemail J. (1995) Peroxidase-catalysed oxidation of different dibenzazepine derivatives. Arch. Pharm. (Weinheim) 328:109-112.
Liégeois J.-F., Bruhwyler J., Petit C., Damas J., Delarge J., Géczy J., Kauffmann J.-M., Lamy M., Meltzer H., Mouithys-Mickalad A. (1999) Oxidation sensitivity may be a useful tool for the detection of the hematotoxic potential of newly developed molecules: Application to antipsychotic drugs. Arch. Biochem. Biophys. 370:126-137.
Ohnishi T., Yarnazaki H., Iyanagi T., Nakamura T., Yamazaki I. (1969) One-electron-transfer reactions in biochemical systems: II. The reaction of free radicals formed in the enzymatic oxidation. Biochim. Biophys. Acta 172:357-369.
Harman L.S., Carver D.K., Schreiber J., Mason R.P. (1986) One- and two-electron oxidation of reduced glutathione by peroxidases. J. Biol. Chem. 261:1642-1648.
Buege J.A., Aust S.D. (1978) Microsomal lipid peroxidation., Methods in Enzymology; Fleischer, S., Packer, L., Eds.; Academic Press: London. Biomembranes. Part C: Biological oxidations microsomal, cytochromes P-450, and other hemoprotein systems; 52:302-310.
Dalla Libera A., Scutari G., Boscolo R., Rigobello M.P., Bindoli A. (1998) Antioxidant properties of clozapine and related neuroleptics. Free Radical Res. 29:151-157.
Nasir A.I., Gundersen L.-L., Rise F., Antonsen O., Kristensen T., Langhelle B., Bast A., Custers I., Haenen G.R.M.M., Wikström H. (1998) Inhibition of lipid peroxidation mediated by indolizines. Bioorg. Med. Chem. Lett. 8:1829-1832.
Liégeois J.-F., Mouithys-Mickalad A., Bruhwyler J., Delarge J., Petit C., Kauffmann J.-M., Lamy M. (1997) JL 13, a potential successor to clozapine, is less sensitive to oxidative phenomena. Biochem. Biophys. Res. Commun. 238:252-255.
Petit C., Quilinc A., Quilinc E., Ortiz Borondo G., Liégeois J.-F., Kauffmann J.-M. (1998) Horseradish peroxidase electrode for phenothiazine analysis. Electroanalysis 10:1241-1248.
Vincent P.C. (1986) Drug-induced aplastic anaemia and agranulocytosis incidence and mechanisms. Drugs 31:52-63.
Pisciotta A.V. (1990) Drug induced agranulocytosis peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev. 4:226-237.
Reynolds J.E.F. Martindale, the Extra Pharmacopoiea, The Pharmaceutical Press: London; 1989.
Kaufman D.W., Kelly J.P., Jurgelon J.M., Anderson T., Issaragrisil S., Wilhom B.-E., Young N.S., Leaverton P., Levy M., Shapiro S. (1996) Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur. J. Haematol. 57:23-30.
Mason R.P., Fischer V. (1992) Possible role of free radical formation in drug-induced agranulocytosis. Drug Safety 7:45-50.
Flynn S.W., Altman S., MacEwan G.W., Black L.L., Greenidge L.L., Honer W.G. (1997) Prolongation of clozapine-induced granulocytopenia associated with olanzapine. J. Clin. Psychopharmacol. 17:494-495.
Wray C.-M., Sztuke-Fournier A. (1998) Olanzapine: Hematological reactions. C. M. A. J. 14:81-82.
Beasley C.M. (1997) Safety of olanzapine. J. Clin. Psychiatry 58:13-17.
Brown G.R., Radford J. (1997) Sertindole hydrochloride: A novel antipsychotic medication with a favorable side effect profile. South. Med. J. 90:691-693.
Casey D.E. (1997) The relationship of pharmacology to side effects. J. Clin. Psychiatry 58:55-62.
Daniel D.G., Goldberg T.E., Weinberger D.R., Kleinman J.E., Pickar D., Lubick L.J., Williams T.S. (1996) Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: A pilot study. Am. J. Psychiatry 153:417-419.
Fulton B., Goa K.L. (1997) Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281-298.
Werapongset W., Chaisirikul S., Chrujiporn W., Visanuyothin T., Kessawai D., Charisilp C., Ratanachata N., Sanichwannakul K., Wangdee P., Bunditchate A., Ukranand P. J. Med. Assoc. Thailand 1998, 81:324-328.
Tugnait M., Hawes E.M., McKay G., Eichelbaum M., Midha K.K. (1999) Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem. Biol. Interact. 118:171-189.
Von Stock B., Spiteller G., Heipertz R. (1977) Austausch aromatisch gebundenen halogens gegen OH- und SCH3- bei der metabolisierung des clozapins im menschlichen körper. Arzneim. Forsch. 27:982-990.
Lai W.G., Gardner I., Zahid N., Uetrecht J.P. (2000) Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: Implications for fluperlapine-induced agranulocytosis. Drug Metab. Dispos. 28:255-263.
Kauffmann J.-M., Viré J.-C., Patriarche G.J. (1984) Tentative correlation between the electrochemical oxidation of neuroleptics and their pharmacological properties. Bioelectrochem. Bioenerg. 12:413-420.
Kauffmann J.-M., Patriarche G.J., Genies E.M. (1982) Comportement électrochimique anodique de neuroleptiques en milieu aqueux et nonaqueux. Electrochim. Acta 27:721-727.
Green M.J., Hill A.O. (1984) Chemistry of dioxygen., Methods in Enzymology; Packer, L., Ed.; Academic Press: London. Oxygen radicals in biological systems; 105:3-22.
